Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Revotar Biopharmaceuticals AG has been awarded funding of the German Federal Ministry of Education and Research

16 Aug 2005 - Revotar Biopharmaceuticals AG announced that it has been awarded funding of the German Federal Ministry of Education and Research (BMBF) to intensify its selectin antagonist discovery programme. The funding totals 427.987 Euros and will be paid over a two-year period. The funding will be provided by the "BioChancePLUS-2" programme of the BMBF and supports Revotar´s activites to design novel anti-inflammatory selectin antagonists to be developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
 
The project is headed by Gerhard Wolff, M.D., Vice President R&D of Revotar, assisted by Ewald Aydt, Ph.D., Director Discovery of Revotar. The project is a significant contribution to Revotar`s strategy to develop selectin antagonists as small molecule drugs (SMD) for inflammatory diseases, stated Stephan Tarlach, CEO of Revotar. In addition, the awarded funding reflects the contineously growing confidence in the business concept of Revotar, added Marc Voigt, CFO of Revotar.